Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Simultaneous Amplification of HER-2 (ERBB2) and Topoisomerase II&#945; (TOP2A) Genes - Molecular Basis for Combination Chemotherapy in Cancer

28 Oct 2006

Abstract excerpt

The HER-2 (also known as ERBB2/ErbB2/c-erbB2/HER-2/neu) oncogene is the most frequently amplified oncogene in breast cancer and is also amplified in other forms of cancer. Beside its important role in tumor induction, growth and progression, HER-2 is also a target for new therapeutic approaches such as Herceptin (trastuzumab), a recombinant antibody designed to block signaling through the HER-2 receptor. In...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to HER2/EGFR in Cancer Research
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 17100565
DOI: 10.2174/156800906778742497

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Simultaneous Amplification of HER-2 (ERBB2) and Topoisomerase II&#945; (TOP2A) Genes - Molecular Basis for Combination Chemotherapy in CancerPMID 17100565Read ↗

Triple negative breast cancer - current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessmentSemantic proximity Read ↗

Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.Semantic proximity Read ↗

ERBB2 and TOP2A in Breast Cancer: A Comprehensive Analysis of Gene Amplification, RNA Levels, and Protein Expression and Their Influence on Prognosis and PredictionSemantic proximity Read ↗

The HER2 amplicon in breast cancer: Topoisomerase IIA and beyondSemantic proximity Read ↗

HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.Semantic proximity Read ↗

HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics.Semantic proximity Read ↗

HER-2/neu and Topoisomerase IIα Gene Amplification and Protein Expression in Invasive Breast CarcinomasSemantic proximity Read ↗

The role of topoisomerase IIα and HER-2 in predicting sensitivity to anthracyclines in breast cancer patientsSemantic proximity Read ↗

Recent Developments in Combination Chemotherapy for Colorectal and Breast Cancers with Topoisomerase InhibitorsSemantic proximity Read ↗

Activation of multiple cancer-associated genes at the <i>ERBB2</i> amplicon in breast cancerSemantic proximity Read ↗

The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized MedicineSemantic proximity Read ↗

Aberrations of <i>ERBB2</i> and <i>TOP2A</i> genes in breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.